Daré Bioscience, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Daré Bioscience, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.7 times its market value (net cash). Higher than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-27.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 62% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 90%
Sales fell 90% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-90% / -26%In 3 years sales changed by -90% while total assets changed by -26%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-4.7×Operating cash was negative last year, while some debt falls due within a year.
Higher than 60% of Healthcare companies in United States.
Cash Cushion Ratio
1.7× cashCash, after subtracting all debt, is 1.7 times its market value (net cash).
Higher than 94% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Daré Bioscience, Inc. made a loss over the last year. Daré Bioscience, Inc. owes $1.02 for every $1 it owns. Daré Bioscience, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossDaré Bioscience, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-22.89Daré Bioscience, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$13 MThe total market value of all of Daré Bioscience, Inc.'s shares at today's price (share price × number of shares), smaller than 85% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeDaré Bioscience, Inc.'s net worth is negative ($1 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.02×Daré Bioscience, Inc. owes $1.02 for every $1 it owns, so it owes more than it owns, higher than 88% of Healthcare companies in United States.
Dividend yield
NoneDaré Bioscience, Inc. does not currently pay a dividend.
Revenue growth
+10429%Revenue rose 10429% in the year to Dec 2025, and shrank 53% a year on average over 3 years.
Profit growth
LossDaré Bioscience, Inc. made a loss in each of the last two years.
Profit margin
-1300.7%Daré Bioscience, Inc. lost $1301 for every $100 of revenue.
Cash vs debt
Net cashDaré Bioscience, Inc. held $22 M more cash than debt (net cash) at Dec 2025.
Questions
How much does Daré Bioscience, Inc. owe compared with what it owns?
Daré Bioscience, Inc. owes $1.02 for every $1 it owns, so it owes more than it owns, higher than 88% of Healthcare companies in United States.
Does Daré Bioscience, Inc. pay a dividend?
No. Daré Bioscience, Inc. does not currently pay a dividend.
Is Daré Bioscience, Inc.'s revenue growing?
Revenue rose 10429% in the year to Dec 2025, and shrank 53% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.